Last updated: April 23, 2026
Who supplies mefenamic acid to pharma and generics markets?
Mefenamic acid is supplied globally as active pharmaceutical ingredient (API) and as intermediates/key building blocks for formulation, dose manufacturing, and scale-up. The market typically sources through three channels:
- API manufacturers producing mefenamic acid (most common for generics and CDMO feedstock).
- Intermediates suppliers supporting upstream synthesis (not always disclosed on invoices as “API”).
- Distribution networks supplying API lots to formulation sites (often re-packaged and documentation-ready).
The key practical point for procurement is that mefenamic acid supply is usually governed by documentation and regulatory readiness (e.g., CoA, DMF/CEP where applicable, GMP compliance, particle spec for the final API grade), not by exclusivity.
Which supplier types and documentation are standard for mefenamic acid transactions?
For mefenamic acid, buyers typically enforce these supply requirements:
- GMP manufacturing for API (site-specific; buyer needs the manufacturing authorization status for the lot’s origin).
- Lot-level CoA covering assay, impurities, and physical attributes.
- Specification alignment to pharmacopeia acceptance (where buyers reference USP/EP monographs).
- Change control via CoC/notification (crucial when polymorph or impurity profiles shift).
- Analytical method package (HPLC/UV methods, impurity standards) for quality transfer.
What procurement specs matter most for mefenamic acid?
Mefenamic acid procurement usually focuses on these technical points:
- Assay (API content) and impurities profile (single and total impurities).
- Particle properties when relevant to dose manufacture (flow, sieve fraction, D50 if specified).
- Residues if solvent routes are used (Class 2/3 solvents and elemental impurities depending on the buyer’s ICH alignment).
- Salt/form availability is less common because mefenamic acid is primarily used in the acid form for oral products, but buyer specifications still govern.
How to interpret “supplier” listings for mefenamic acid?
“Supplier” lists online often mix:
- Manufacturers (own synthesis and final API release),
- distributors (repackage and resell), and
- traders (commodity sourcing without guaranteed upstream traceability).
For high-stakes supply continuity, buyers prioritize:
- named API manufacturing site, not just the trading brand;
- the exact grade (mefenamic acid USP/EP-like spec);
- whether GMP certificate and regulatory dossier support (DMF/CEP) exist for that site.
What does the supply landscape look like by region?
Mefenamic acid typically shows broad availability across:
- India (large generic API ecosystem with many API-grade producers),
- China (bulk API capacity and established chemical manufacturing),
- EU/US-qualified supply is more limited for this molecule, often supplied through global API sites plus distributors.
This matters because procurement risk often concentrates in:
- documentation gaps (DMF/CEP availability),
- impurity drift during process changes,
- lead time variability tied to batch windows.
Supplier shortlists: what categories should be targeted?
Because the request is “Suppliers,” the actionable way to structure vendor outreach for mefenamic acid is:
- Category A: API manufacturers with demonstrated GMP release and stable impurity profiles.
- Category B: Regulated distributors that provide full lot documentation and traceability to the manufacturing site.
- Category C: Intermediates suppliers only when a buyer runs in-house crystallization, milling, or formulation using a controlled upstream input.
The fastest pathway to scale production is usually Category A with a fallback through Category B if qualification timelines constrain direct onboarding.
Key supply due-diligence checklist for mefenamic acid
Before PO placement, vendors should be able to provide or support:
- GMP status for the API manufacturing site
- CoA for representative lots (assay + impurity list)
- Specification sheet (assay range, impurity limits, test methods)
- Stability data if shelf life is buyer-critical
- Impurity reference standards availability or validation approach
- Change notification history (process changes, site changes, raw material sources)
Key Takeaways
- Mefenamic acid supply is typically broad and non-exclusive, with procurement governed by GMP documentation and impurity/spec alignment rather than scarcity.
- “Suppliers” in market listings often mix API manufacturers and distributors; qualification should anchor to the API manufacturing site and lot traceability.
- Procurement risk concentrates in documentation completeness, impurity profile stability, and lead time/batch availability, not in access to chemical feedstock.
FAQs
1) Are mefenamic acid suppliers usually API manufacturers or distributors?
Both. Many listings are distributors. Qualification should target the API manufacturing site that released the specific lot.
2) What documentation matters most when buying mefenamic acid API?
Lot CoA, GMP status for the manufacturing site, full specification (assay/impurities), and method support aligned to buyer acceptance criteria.
3) Do buyers need polymorph considerations for mefenamic acid?
Mefenamic acid is typically traded as the acid form; buyers still enforce physical specs and impurity profiles, and they may add polymorph controls if their process is sensitive.
4) What drives lead time for mefenamic acid supply?
Batch schedules, documentation readiness, and impurity-spec tuning during manufacturing changes.
5) How do buyers reduce supply disruption risk?
Qualify at least two sources: a primary API manufacturer and a secondary regulated distributor or alternate API site.
References
[1] ICH. ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
[2] ICH. ICH Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities).
[3] ICH. ICH Q3A(R2): Impurities in New Drug Substances.
[4] ICH. ICH Q3B(R2): Impurities in New Drug Products.
